The U.S. biologicals market is entering the 2026 growing season with a different proposition: biological products are increasingly being evaluated not simply by whether they can replace conventional crop inputs, but by how effectively they can become part of a broader production system. The shift matters for growers, crop consultants and ag retailers because biologicals are moving deeper into programs that combine crop protection, plant nutrition, stress management and agronomic decision-making. Rather than a biological-versus-chemistry contest, the emerging model is one in which different technologies are expected to perform complementary jobs within the same acre.

That distinction is particularly relevant in U.S. row crops. A 2026 survey of 90 agricultural industry respondents was heavily connected to corn, soybeans and wheat: 97% serviced corn, 82% soybeans and 62% wheat. Most respondents were ag retailers, cooperatives or crop consultants, and 43% were based in the Midwest. The market snapshot therefore captures an important part of commercial agriculture where biological products must prove themselves not in controlled environments, but across large acreage, variable soils, unpredictable weather and production systems already built around established crop protection and fertility programs.

Biologicals

Biologicals Gain Ground in Latin America, but Where Do They Really Fit in the Grower's Toolbox?

The numbers also show that biologicals are becoming a broader category rather than a single-product story. Biostimulants represented 50% of biological products sold by surveyed ag retailers during the 2025 growing season, compared with 32% for biofertilizers and 18% for biopesticides. At the retailer level, 84% of respondents sold biostimulants, 54% biofertilizers and 30% biopesticides. Those percentages suggest that growers increasingly encounter biological technologies serving different agronomic functions rather than one universal solution.

From Input Replacement to Integrated Crop Management

The significance of that diversification is larger than market share. Biologicals can influence different parts of crop production, from nutrient availability and root development to plant stress response and pest management. That makes the old question - "Can biologicals replace chemistry?" - increasingly restrictive. The more important agronomic question is where a biological fits within a crop program, under which field conditions it generates a measurable response, how it interacts with other inputs and whether that response produces enough economic value to justify its place in the production system.

This is also where the biologicals sector faces one of its biggest challenges: grower confidence. The 2026 industry survey identifies product trust as a continuing concern, reflecting longstanding questions about whether biological products consistently deliver the results expected under commercial field conditions. For U.S. growers operating on tight margins, biological adoption ultimately depends on more than an attractive mode of action. Performance must remain sufficiently repeatable across different soils, environments, cropping systems and application conditions to support a defensible return on investment.

That requirement changes how biological innovation should be evaluated. A microorganism, metabolite or plant-derived compound may perform well during discovery, yet commercial agriculture adds multiple layers of variability. Formulation, shelf life, storage, application timing, placement, environmental conditions and compatibility with complementary inputs can influence the final outcome. This helps explain why the industry is moving toward a systems approach: biological performance is increasingly tied not only to what is inside the container, but also to how the technology is positioned and managed from distribution through field application.

The shift is especially important for corn and soybean production, where growers already manage seed genetics, fertility, herbicides, fungicides, insecticides, soil conditions and increasingly sophisticated digital information. Biologicals are entering that existing architecture rather than building a separate one. Their long-term opportunity may therefore come from filling specific agronomic gaps: supporting nutrient efficiency, improving stress management, complementing crop protection programs or providing additional modes of action where conventional strategies face limitations.

The Next Competition Is for Predictable Performance Per Acre

Data could become one of the technologies that accelerates this transition. Research summarized in 2026 describes the use of machine learning combined with environmental and soil datasets to predict where and when particular biologicals may perform best. The same approach can support decisions involving application timing, placement and complementary inputs. AI-guided screening is also being explored for formulation performance, encapsulation and controlled release, addressing persistent challenges such as limited shelf life and inconsistent field responses.

For growers, that development could be more important than simply adding another biological product to the market. If soil characteristics, weather, crop stage and field history can help identify the environments where a biological has the highest probability of response, precision agriculture and biologicals begin to converge. Instead of treating every acre identically, biological inputs could increasingly be positioned according to agronomic conditions. The concept resembles the evolution already seen in variable-rate fertility and precision seeding: better targeting can become as important as the technology being applied.

There is another important message in the market data. Biofertilizers were sold by 54% of surveyed retailers in both 2025 and 2026, while the percentage selling biopesticides increased from 29% to 30%. These are not explosive year-over-year shifts, but they indicate a category moving through a more demanding stage of commercialization. Once biologicals move beyond early adoption, the benchmark changes: growers and advisers expect evidence, repeatability and economic justification comparable to the scrutiny applied to other crop inputs.

The U.S. experience also connects directly with Latin America, where biological technologies are expanding across large-scale soybean, corn and other cropping systems. The two regions have different regulatory structures and agronomic environments, but they increasingly share the same challenge: moving biologicals from promising technologies toward repeatable components of commercial crop management. That creates opportunities for field research across different climates, soils and production systems while reinforcing the importance of local validation rather than assuming that performance observed in one geography will automatically transfer to another.

The larger transformation, then, is not about choosing one side of a biological-versus-chemistry divide. Biologicals do not need to eliminate conventional crop protection or fertility tools to reshape agriculture. Their bigger opportunity is to change how those tools are combined, targeted and evaluated across the production system. If biological innovation becomes increasingly connected with agronomy, field data, precision agriculture and measurable return per acre, the winners will not necessarily be the technologies that promise to replace the most inputs. They will be those that prove exactly where they belong in the system - and what measurable value they add to every acre.